ATE440618T1 - Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs. - Google Patents

Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.

Info

Publication number
ATE440618T1
ATE440618T1 AT01948684T AT01948684T ATE440618T1 AT E440618 T1 ATE440618 T1 AT E440618T1 AT 01948684 T AT01948684 T AT 01948684T AT 01948684 T AT01948684 T AT 01948684T AT E440618 T1 ATE440618 T1 AT E440618T1
Authority
AT
Austria
Prior art keywords
cancer
prevention
treatment
cpg
combination
Prior art date
Application number
AT01948684T
Other languages
English (en)
Inventor
George Weiner
Gunther Hartmann
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Application granted granted Critical
Publication of ATE440618T1 publication Critical patent/ATE440618T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01948684T 2000-06-22 2001-06-22 Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs. ATE440618T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21334600P 2000-06-22 2000-06-22
PCT/US2001/020154 WO2001097843A2 (en) 2000-06-22 2001-06-22 Methods for enhancing antibody-induced cell lysis and treating cancer

Publications (1)

Publication Number Publication Date
ATE440618T1 true ATE440618T1 (de) 2009-09-15

Family

ID=22794755

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01948684T ATE440618T1 (de) 2000-06-22 2001-06-22 Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.

Country Status (12)

Country Link
US (1) US7534772B2 (de)
EP (1) EP1296714B1 (de)
JP (1) JP2003535907A (de)
AT (1) ATE440618T1 (de)
AU (5) AU7013401A (de)
CA (1) CA2410371C (de)
DE (1) DE60139689D1 (de)
DK (1) DK1296714T3 (de)
ES (1) ES2332444T3 (de)
PT (1) PT1296714E (de)
SI (1) SI1296714T1 (de)
WO (1) WO2001097843A2 (de)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1997028259A1 (en) * 1996-01-30 1997-08-07 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
DE69935507T2 (de) * 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
JP2002514397A (ja) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
DE69932717T2 (de) * 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
DK2204186T3 (en) 1999-02-17 2016-07-18 Csl Ltd Immunogenic complexes, and related methods
EP1176966B1 (de) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
KR20020027311A (ko) * 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
CN1373672A (zh) * 1999-07-12 2002-10-09 杰南技术公司 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
PL354997A1 (en) * 1999-09-25 2004-03-22 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1311288A1 (de) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunstimulierende nukleinsäuren zur induktion einer th-2 immunreaktion
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040131628A1 (en) * 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2001091807A2 (en) 2000-06-02 2001-12-06 Board Of Regents Ethylenedicysteine (ec)-drug conjugates
WO2001093902A2 (en) * 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
US6943240B2 (en) * 2000-09-15 2005-09-13 Coley Pharmaceuticals Gmbh Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
TWI283575B (en) * 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
DE60134421D1 (de) * 2000-12-08 2008-07-24 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US20030072762A1 (en) * 2001-08-03 2003-04-17 Van De Winkel Jan G. J. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance Fc receptor-mediated immunotherapies
WO2003014294A2 (en) * 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
NZ552377A (en) 2001-08-17 2008-08-29 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
NZ531612A (en) 2001-09-07 2006-01-27 Univ Boston Method and composition for treating immune complex associated disorders
WO2003031573A2 (en) * 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
EP1478371A4 (de) * 2001-10-12 2007-11-07 Univ Iowa Res Found Verfahren und produkte zur verbesserung der immunantworten mit imidazochinolin-verbindungen
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
EP1474432A1 (de) 2002-02-04 2004-11-10 Biomira Inc. Immunstimulierende, kovalent lipid-modifizierte oligonukleotide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
ES2543710T3 (es) 2002-04-04 2015-08-21 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimulantes que contienen G y U
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
CA2513143A1 (en) * 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) * 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
BR0313033A (pt) * 2002-07-25 2007-07-10 Genentech Inc anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
SG166673A1 (en) * 2002-08-19 2010-12-29 Coley Pharm Group Inc Immunostimulatory nucleic acids
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
DK2241325T3 (da) 2002-10-29 2012-04-10 Coley Pharm Group Inc Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
CN103833854B (zh) * 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
AU2004218090A1 (en) * 2003-03-04 2004-09-16 Sosei Co., Ltd. GM-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
ES2528631T3 (es) * 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
EP1613350B1 (de) 2003-04-09 2009-03-18 Genentech, Inc. Behandlung von autoimmunkrankheit bei einem patienten mit unzureichendem ansprechen auf einen tnf-alpha-hemmer
EP1628531A4 (de) * 2003-05-16 2010-06-30 Idera Pharmaceuticals Inc Synergistische behandlung von krebs durch gemeinsame verwendung von immunomeren und chemotherapeutika
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
PT1631313E (pt) * 2003-06-05 2015-07-02 Genentech Inc Terapêutica de combinação para distúrbios de células b
BRPI0411514A (pt) * 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
KR20060052921A (ko) * 2003-07-29 2006-05-19 제넨테크, 인크. 인간 항 ｃｄ20 항체 어세이 및 그 용도
RU2006110036A (ru) * 2003-08-29 2006-08-10 Дженентек, Инк. (Us) Лечение глазных расстройств анти-cd20
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
WO2005034979A2 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
EA008741B1 (ru) * 2003-10-30 2007-08-31 Коли Фармасьютикал Гмбх Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US20050186206A1 (en) * 2003-12-19 2005-08-25 Genentech, Inc. Detection of CD20 in therapy of autoimmune diseases
WO2005061542A2 (en) * 2003-12-19 2005-07-07 Genentech, Inc. Detection of cd20 in transplant rejection
CA2550058C (en) * 2003-12-19 2016-07-12 Antisense Pharma Gmbh Pharmaceutical composition comprising a tgf-beta2 antisense oligonucleotide and a chemotherapeutic
CA2555390C (en) * 2004-02-19 2014-08-05 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
CA2560108A1 (en) * 2004-04-02 2005-11-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing il-10 responses
WO2005113003A2 (en) * 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
EP1740946B1 (de) 2004-04-20 2013-11-06 Genmab A/S Humane monoklonale antikörper gegen cd20
WO2005117972A2 (en) * 2004-05-05 2005-12-15 Genentech, Inc. Preventing autoimmune disease by using an anti-cd20 antibody
EP2374815A1 (de) * 2004-05-28 2011-10-12 IDEXX Laboratories, Inc. Hunden CD20 Zusammensetzungen
DOP2005000108A (es) * 2004-06-04 2007-06-15 Genentech Inc Method for treating lupus
TW201422238A (zh) * 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
EP2484374A1 (de) * 2004-07-18 2012-08-08 CSL Limited Immunstimulierender Komplex und Oligonucleotidformulierungen zur Induzierung verbesserter Interferon-Gamma-Antworten
WO2006012508A2 (en) * 2004-07-22 2006-02-02 Genentech, Inc. Method of treating sjögren's syndrome
CA2580271A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2006052900A2 (en) 2004-11-09 2006-05-18 University Of Southern California Targeted innate immunity
JP2008526998A (ja) * 2005-01-13 2008-07-24 ジェネンテック・インコーポレーテッド 治療方法
JP2008528497A (ja) * 2005-01-20 2008-07-31 プロジェニックス ファーマシューティカルズ，インコーポレーテッド メチルナルトレキソンおよび関連化合物の術後性胃腸障害のための使用
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
KR101335798B1 (ko) * 2005-02-15 2013-12-02 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
AU2006216493A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
SI1859793T1 (sl) * 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) * 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
CN101193646A (zh) * 2005-04-08 2008-06-04 科勒制药集团公司 治疗传染病加剧性哮喘的方法
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
CA2609788A1 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
AU2006244445B2 (en) * 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
CN1865275B (zh) 2005-05-17 2011-06-15 长春华普生物技术有限公司 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
US7601335B2 (en) * 2005-05-20 2009-10-13 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US8148341B2 (en) 2005-07-01 2012-04-03 Index Pharmaceuticals Ab Method for modulating responsiveness to steroids
EP1901759B1 (de) 2005-07-01 2010-08-04 Index Pharmaceuticals AB Immunstimulatorisches verfahren
CN101268101A (zh) * 2005-07-07 2008-09-17 科利制药集团公司 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
WO2007014238A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
JP2010503608A (ja) * 2005-09-16 2010-02-04 コーリー ファーマシューティカル ゲーエムベーハー ホスホジエステルバックボーンを有する免疫刺激性一本鎖リボ核酸
SG165394A1 (en) * 2005-09-16 2010-10-28 Coley Pharm Gmbh Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
WO2007050034A1 (en) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
GB0523041D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) * 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007062107A2 (en) * 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
PT1991678E (pt) * 2006-02-15 2015-11-25 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleótidos
EP2418223A3 (de) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Einkettige, multivalente Bindungsproteine mit Effektorfunktion
US20080031887A1 (en) * 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
JP2010507361A (ja) * 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー 具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
DE102006035618A1 (de) * 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
RS53263B (sr) 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
PA8774201A1 (es) * 2007-03-29 2009-06-23 Progenics Pharm Inc Antagonista del receptor
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
US20100226917A1 (en) * 2007-04-27 2010-09-09 Astrazeneca Ab Methods for the treatment of hematologic malignancies
EP2573176B1 (de) * 2007-05-04 2016-04-06 InDex Pharmaceuticals AB Tumorwachstumshemmende Verbindungen und Verfahren zu ihrer Verwendung
PL4365189T3 (pl) 2007-07-09 2025-05-26 F. Hoffmann-La Roche Ag Zapobieganie redukcji wiązania disiarczkowego podczas rekombinacyjnego wytwarzania polipeptydów
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
CA2699265A1 (en) * 2007-09-13 2009-03-19 Molecular Insight Pharmaceuticals, Inc. Infusion and transfer system for use with radioactive agents
EP2233149B1 (de) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Kombination von Transmembran-Aktivator und Calcium-Modulator und Cyclophilin Ligand Interaktor (TACI) und anti-CD20 Mitteln zur Behandlung von Autoimmunerkrankungen
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
EP3346005A1 (de) 2008-01-31 2018-07-11 CureVac AG Nukleinsäuren der formel (i) (nuglxmgnnv)a und derivate davon als immunstimulierendes mittel/adjuvans
CN101959892B (zh) * 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
US8685995B2 (en) * 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
SG189772A1 (en) 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2300022A2 (de) 2008-04-25 2011-03-30 Duke University Regulierende b-zellen und ihre verwendungszwecke
EP2307002B1 (de) 2008-06-09 2013-01-02 Cyclacel Limited Kombinationen von sapacitabin oder cndac mit dna-methyltransferase-inhibitoren wie decitabin und procain
JP2011524899A (ja) * 2008-06-18 2011-09-08 インデックス・ファーマシューティカルズ・アクチエボラーグ がんの併用療法
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
EA023148B1 (ru) * 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110280934A1 (en) * 2008-11-04 2011-11-17 Asa Karlsson Increased Expression of Specific Antigens
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010132622A2 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of California Anticd20-cpg conjugates and methods of treating b cell malignancies
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
US20130224237A1 (en) * 2010-07-20 2013-08-29 University Of Miami Inhibition of nonsense mediated decay pathways
ES2558106T3 (es) 2010-07-30 2016-02-02 Curevac Ag Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
US10131875B2 (en) 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
US9044474B2 (en) * 2010-11-08 2015-06-02 The Ohio State University Compositions and methods for increasing drug efficacy in cancer
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
JP5930146B2 (ja) * 2011-03-28 2016-06-08 国立研究開発法人物質・材料研究機構 免疫刺激オリゴヌクレオチドおよび前記免疫刺激オリゴヌクレオチドを含む治療剤
ES2743691T3 (es) 2011-04-14 2020-02-20 Cyclacel Ltd Régimen de dosis para sapacitabina y decitabina en combinación para tratar la leucemia mieloide aguda
US20130157261A1 (en) * 2011-06-01 2013-06-20 The Methodist Hospital Research Institute Compositions and Methods for Quantitative Histology, Calibration of Images in Fluorescence Microscopy, and ddTUNEL Analyses
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
MX369469B (es) 2013-08-21 2019-11-08 Curevac Ag Vacuna contra el virus respiratorio sincitial.
US10436680B2 (en) 2013-10-15 2019-10-08 Kianoosh Peyvan Capture, disruption, and extraction apparatus and method
CN106170299A (zh) * 2014-01-22 2016-11-30 小利兰斯坦福大学托管委员会 用于抗体和抗体负载树突状细胞介导治疗的方法和组合物
EP3129050A2 (de) 2014-04-01 2017-02-15 CureVac AG Polymerträger-cargo-komplex zur verwendung als immunstimulierendes mittel oder als ein adjuvans
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114057885A (zh) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
EP3365375A4 (de) * 2015-10-20 2019-09-04 Sorrento Therapeutics, Inc. Verbindungen zur intrazellulären verabreichung
US20190185852A1 (en) * 2016-05-05 2019-06-20 M. Mahmood Hussain Therapeutically modulating apob and apoai
EP3484518B1 (de) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Antikörper-adjuvanzkonjugate
EP3554515A4 (de) 2016-12-15 2020-08-26 Duke University Antikörper und verfahren zur abreicherung von regulatorischen b10-zellen und verwendung in kombination mit immuncheckpoint-inhibitoren
IL269970B (en) 2017-04-14 2022-09-01 Tallac Therapeutics Inc Polynucleotides that modulate the immune system, their antibody binding, and methods of using them
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
CN111826764B (zh) * 2020-07-28 2021-10-15 吴忠德悦纺织科技有限公司 一种改性多组份复合纱线的制备方法
CN114216985A (zh) * 2021-12-22 2022-03-22 珠海润都制药股份有限公司 一种异山梨醇中硫酸二异丙酯的检验方法

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
ATE75483T1 (de) 1981-10-23 1992-05-15 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
FR2596144B1 (fr) 1986-03-24 1988-05-27 Jouet Etienne Echangeur de chaleur spirale et son procede de fabrication
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5565354A (en) 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
DE3861646D1 (de) 1987-07-23 1991-02-28 Uop Inc Behandlung eines temperaturempfindlichen altoelstromes, welcher nichtdestillierbare komponenten enthaelt.
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5786189A (en) 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5506212A (en) 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5248670A (en) 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
HUT63430A (en) 1990-08-16 1993-08-30 Isis Pharmaceuticals Inc Process for producing oligonucleotides influencing the effect of cytomegalovirus infection
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5208146A (en) * 1990-11-05 1993-05-04 The Regents Of The University Of California Murine monoclonal anti-idiotype antibodies
US5512668A (en) 1991-03-06 1996-04-30 Polish Academy Of Sciences Solid phase oligonucleotide synthesis using phospholane intermediates
US5683985A (en) 1991-04-18 1997-11-04 The Salk Institute For Biological Studies Oligonucleotide decoys and methods relating thereto
WO1992021353A1 (en) 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers
US5359052A (en) 1991-08-05 1994-10-25 Polish Academy Of Sciences Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
JPH09501936A (ja) 1993-08-26 1997-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性ペプチドをコードする裸のポリヌクレオチドを投与するための方法、組成物および装置
EP0731809A4 (de) 1993-11-16 1998-10-21 Genta Inc Chiral angereicherte synthetische phosphonatoligomere
US6727230B1 (en) 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JPH10502820A (ja) 1994-07-18 1998-03-17 ユニバーシティ・オブ・ノース・カロライナ・アット・チャペル・ヒル 腫瘍増殖、浸潤および転移を阻害するためのオリゴヌクレオシド化合物および方法
ES2220929T3 (es) 1995-05-11 2004-12-16 Applied Research Systems Ars Holding N.V. Inhibidor de la actividad il-6.
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5969135A (en) * 1995-11-02 1999-10-19 Icn Pharmaceuticals, Inc. Oligonucleotide analogs with an amino acid or a modified amino alcohol residue
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
WO1997028259A1 (en) 1996-01-30 1997-08-07 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US5856465A (en) 1996-05-24 1999-01-05 Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (de) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE441432T1 (de) * 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
US6221882B1 (en) 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
WO1999056755A1 (en) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2002514397A (ja) 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
KR101063278B1 (ko) * 1998-08-11 2011-09-07 바이오겐 아이덱 인크. Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
WO2000014217A2 (en) 1998-09-03 2000-03-16 Coley Pharmaceutical Gmbh G-motif oligonucleotides and uses thereof
EP1131093A4 (de) * 1998-11-09 2002-05-02 Idec Pharma Corp Behandlung hämatologischer bösartigkeiten assoziiert mit zirkulierenden tumorzellen unter verwendung chimärer anti-cd20 antikörper
ATE275727T1 (de) 1999-04-29 2004-09-15 Coley Pharm Gmbh Screening nach modulatoren der funktion von immunstimulatorischer dna
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU5937100A (en) * 1999-06-23 2001-01-09 Datum, Inc. System and method for providing a trusted third party clock and trusted local clock
PL354997A1 (en) 1999-09-25 2004-03-22 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1311288A1 (de) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunstimulierende nukleinsäuren zur induktion einer th-2 immunreaktion
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
US20020091097A1 (en) 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
US6943240B2 (en) 2000-09-15 2005-09-13 Coley Pharmaceuticals Gmbh Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
DE60134421D1 (de) 2000-12-08 2008-07-24 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US20030148316A1 (en) 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
NZ552377A (en) 2001-08-17 2008-08-29 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
WO2003031573A2 (en) 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
EP1478371A4 (de) 2001-10-12 2007-11-07 Univ Iowa Res Found Verfahren und produkte zur verbesserung der immunantworten mit imidazochinolin-verbindungen
ES2543710T3 (es) 2002-04-04 2015-08-21 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimulantes que contienen G y U
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en) 2002-07-17 2004-02-02 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
WO2004026888A2 (en) 2002-09-19 2004-04-01 Coley Pharmaceutical Gmbh Toll-like receptor 9 (tlr9) from various mammalian species
DK2241325T3 (da) 2002-10-29 2012-04-10 Coley Pharm Group Inc Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
AU2004226605A1 (en) 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004094671A2 (en) 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
CA2536139A1 (en) 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
EA008741B1 (ru) 2003-10-30 2007-08-31 Коли Фармасьютикал Гмбх Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CA2555390C (en) 2004-02-19 2014-08-05 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
CA2560108A1 (en) 2004-04-02 2005-11-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing il-10 responses
JP2008501807A (ja) 2004-06-08 2008-01-24 コーリー ファーマシューティカル ゲーエムベーハー 抗原ならびに免疫活性化アゴニストおよび免疫活性化アンタゴニストのための担体基本骨格としての無塩基オリゴヌクレオチド
EP2484374A1 (de) 2004-07-18 2012-08-08 CSL Limited Immunstimulierender Komplex und Oligonucleotidformulierungen zur Induzierung verbesserter Interferon-Gamma-Antworten
CA2574090A1 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
AU2006216493A1 (en) 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
CN101193646A (zh) 2005-04-08 2008-06-04 科勒制药集团公司 治疗传染病加剧性哮喘的方法
CA2609788A1 (en) 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
SG165394A1 (en) 2005-09-16 2010-10-28 Coley Pharm Gmbh Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
AU2006294528A1 (en) 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of TLR-mediated immune responses using adaptor oligonucleotides
WO2007062107A2 (en) 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides

Also Published As

Publication number Publication date
AU2006216542B2 (en) 2009-04-30
AU2009203061C1 (en) 2012-06-28
DK1296714T3 (da) 2009-12-07
CA2410371C (en) 2015-11-17
WO2001097843A3 (en) 2003-01-23
US20030026801A1 (en) 2003-02-06
AU2009212978A1 (en) 2009-10-01
EP1296714A2 (de) 2003-04-02
AU2001270134B2 (en) 2006-06-15
JP2003535907A (ja) 2003-12-02
AU7013401A (en) 2002-01-02
DE60139689D1 (de) 2009-10-08
US7534772B2 (en) 2009-05-19
PT1296714E (pt) 2009-10-15
AU2006216542A1 (en) 2006-10-12
CA2410371A1 (en) 2001-12-27
ES2332444T3 (es) 2010-02-05
EP1296714B1 (de) 2009-08-26
AU2009203061B2 (en) 2012-02-23
WO2001097843A2 (en) 2001-12-27
SI1296714T1 (sl) 2010-01-29
AU2009203061A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
ATE440618T1 (de) Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
WO2001098317A3 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE69738791D1 (de) Methode zur behandlung von biopolymeren, mikroorganismen oder anderen materialien, die mehr als einen typ von magnetischen partikeln benutzt.
DE60109589D1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
DE60005953D1 (de) Stapelbare statische mischelemente
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
EP1085892A4 (de) Impfstrategie zur vorbeugung und behandlung von krebs
ZA200108684B (en) Method of enhancing biological effectiveness of plant treatment compositions.
DE69834693D1 (de) Zusammensetzung zur behandlung von elastischen polyurethanfasern und die damit behandelten fasern
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
ATE546153T1 (de) Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
EP1694364A4 (de) System zur behandlung und prävention von brustkrebs
ATE278441T1 (de) Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60305400D1 (de) Anlage zur Behandlung von Produkten und dazugehörige Datenerfassungseinheit
DE60125212D1 (de) Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen.
BR0111785A (pt) Composições e métodos para tratamento de candidìase
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
DE60119671D1 (de) Verfahren zur Behandlung von Holzwerkstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1296714

Country of ref document: EP